Physician profile
Susie Ro
NPI 1902965643
$6,486.12
in general payments reported to CMS, 2019-2025
29 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.21 · 2023: $1,988 · 2024: $1,707 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,475 · Travel and Lodging: $1,920 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.88 |
| Travel and Lodging | $1,919.68 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,969.30 | 2022-2025 | General - Therapies, Bionic Navigator, Vercise |
| Abbvie INC. | $865.14 | 2023-2025 | Duopa, Botox |
| Teva Pharmaceuticals USA, INC. | $360.54 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Merz Pharmaceuticals, LLC | $256.48 | 2023-2025 | Xeomin, Inbrija |
| Eisai INC. | $221.52 | 2024-2025 | |
| Lilly USA, LLC | $217.66 | 2023-2025 | Kisunla, Amyvid, Reyvow |
| Pfizer INC. | $195.35 | 2023-2025 | |
| Novo Nordisk INC | $187.44 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $185.64 | 2024-2025 | Dysport |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.43 | 2024-2025 | Caplyta |
| Lundbeck LLC | $148.93 | 2025 | Rexulti, Vyepti |
| Acadia Pharmaceuticals INC | $121.17 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $90.79 | 2023-2024 | Ingrezza, Ongentys |
| Biogen, INC. | $70.81 | 2025 | Leqembi |
| Medtronic, INC. | $61.93 | 2022-2023 | Sensight |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $60.05 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $48.96 | 2023-2025 | Nuedexta, Rexulti |
| Mdd US Operations, LLC | $43.46 | 2023 | Gocovri |
| Supernus Pharmaceuticals, INC. | $34.22 | 2024 | Qelbree |
| Impel Pharmaceuticals INC. | $30.74 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $28.40 | 2024 | Rytary |
| Axsome Therapeutics, INC. | $26.32 | 2025 | Auvelity |
| Acorda Therapeutics, INC | $24.95 | 2023 | Inbrija |
| Galderma Laboratories, L.P. | $24.01 | 2024 | |
| Xeris Pharmaceuticals, INC. | $22.34 | 2024 | Keveyis |
| Revance Therapeutics, INC. | $18.27 | 2025 | Daxxify |
| Cala Health, INC. | $17.27 | 2024 | Cala Trio, Cala Kiq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susie Ro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.